Source: Eur Respir J 2015; 45: 1434-1445
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Wollin Lutz, Wex Eva, Pautsch Alexander, Schnapp Gisela, Hostettler Katrin E., Stowasser Susanne, Kolb Martin. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015; 45: 1434-1445

Member's Comments

No comment yet.

Related content which might interest you: A comparison of pirfenidone versus nintedanib for the management of idiopathic pulmonary fibrosis Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage Source: ERJ Open Res, 5 (2) 00127-2018; 10.1183/23120541.00127-2018 Year: 2019 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis Source: ERJ Open Res, 7 (3) 00321-2021; 10.1183/23120541.00321-2021 Year: 2021 Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Evaluation of treatment with Nintedanib in patients with idiopathic pulmonary fibrosis: a proteomical approach Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Antifibrotic choice in idiopathic pulmonary fibrosis Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 50 (4) 1701157; 10.1183/13993003.01157-2017 Year: 2017 Real-life comparison between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis Source: Eur Respir J, 52 (2) 1800230; 10.1183/13993003.00230-2018 Year: 2018 Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF treatment II Year: 2016 Treatment efficacy of idiopathic pulmonary fibrosis depending on the dose difference of pirfenidone Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 The potential impact of azithromycin in idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (2) 1800628; 10.1183/13993003.00628-2018 Year: 2019 The efficacy of anti-fibrotic agents for acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017